In adult sepsis, novel therapeutic options such as interleukin-22, anti-high mobility group box 1 (HMGB1) monoclonal antibody, vascular endothelial growth factor receptor monoclonal antibodies, and recombinant human thrombomodulin (rhTM) are the focus of preclinical investigation8. The gene discussed is THBD; the disease is Sepsis.